Table 1.
Demographic and Clinical Characteristics of the Patients
| Characteristic | N | % |
|---|---|---|
| Age at diagnosis, years | ||
| Median: 59 | ||
| SD: 9.9 | ||
| Range: 46–73 | ||
| Sex | ||
| Male | 2 | 33 |
| Female | 4 | 67 |
| Method of BRAFV600E detection | ||
| Immunohistochemistry | 3 | 50 |
| cfDNA | 3 | 50 |
| T stage at diagnosis | ||
| T4a | 0 | 0 |
| T4b | 6 | 100 |
| N stage at diagnosis | ||
| N0 | 0 | 0 |
| N1a | 1 | 17 |
| N1b | 5 | 83 |
| M stage at diagnosis | ||
| M0 | 4 | 67 |
| M1 | 2 | 33 |
| Bridging chemotherapy | ||
| Carboplatin and abraxane | 1 | 17 |
| Abraxane only | 1 | 17 |
| Paclitaxel | 2 | 33 |
| None | 2 | 33 |
| Surgical resection | ||
| R0 | 4 | 60 |
| R1 | 2 | 40 |
| Dabrafenib/Trametinib administration | ||
| Via gastrostomy tube | 2 | 33 |
| Modified oral administration | 2 | 33 |
| Standard oral administration | 2 | 33 |
| Post-op complications | ||
| Wound infection | 1 | 17 |
| Temporary unilateral vocal cord paresis | 1 | 17 |
| Pulmonary embolism | 1 | 17 |
| Adjuvant chemoradiation | ||
| Yes | 5 | 83 |
| No | 1 | 17 |
| Duration of neoadjuvant treatment, months | ||
| Median: 3.6 | ||
| SD: 3.5 | ||
| Range: 1.6–12 | ||
| Vital status | ||
| Alive without evidence of disease | 4 | 67 |
| Died of disease | 2 | 33 |
| Duration of follow-up from diagnosis, months | ||
| Median: 16.5 | ||
| SD: 6.6 | ||
| Range: 7.8–26.0 | ||
| Duration of follow-up from start of BRAF-Directed therapy, months | ||
| Median: 15.0 | ||
| SD:6.4 | ||
| Range: 6.4–25.2 | ||
cfDNA, circulating cell-free DNA; SD, standard deviation.